Opinion
Video
Author(s):
Key opinion leaders anticipate future developments in HER2-positive breast cancer, and on the potential for translating therapeutic advances from the metastatic landscape into early-stage disease management.
Intrathecal Dendritic Cells Under Evaluation for Leptomeningeal Disease in TNBC and HER2+ Breast Cancer
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Trilaciclib Before Gemcitabine/Carboplatin Misses OS End Point in Metastatic TNBC
Merkow and Connell Highlight Considerations for HAI Pump Use in CRC
European Commission Approves Capivasertib Plus Fulvestrant for ER+ Breast Cancer
The Pursuit of Targeted Agents Broadens the HR+ Breast Cancer Treatment Paradigm
Lunresertib Plus FOLFIRI Shows Safety, Elicits Responses in CCNE1+ or FBXW7+ Advanced GI Tumors
Liso-cel Shows Improved EFS, PFS, and Durable Responses in Second-line LBCL at 3 Years
Lutetium Lu 177 Dotatate Maintains PFS, ORR Benefits Across Subgroups in SSTR+ GEP-NETs
Dostarlimab/Chemo/Niraparib Generates PFS Benefit in Primary/Recurrent Endometrial Cancer